Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries

BackgroundViral load (VL) monitoring is an essential component of the care of HIV positive individuals. Rates of VL monitoring have been shown to vary by HIV risk factor and clinical characteristics. The objective of this study was to determine whether there are differences among regions in Canada in the rates of VL testing of HIV-positive individuals on combination antiretroviral therapy (cART), where the testing is available without financial barriers under the coverage of provincial health insurance programs.MethodsThe Canadian Observational Cohort (CANOC) is a collaboration of nine Canadian cohorts of HIV-positive individuals who initiated cART after January 1, 2000. The study included participants with at least one year of follow-up. Generalized Estimating Equation (GEE) regression models were used to determine the effect of geographic region on (1) the occurrence of an interval of 9 months or more between two consecutive recorded VL tests and (2) the number of days between VL tests, after adjusting for demographic and clinical covariates. Overall and regional annual rates of VL testing were also reported.Results3,648 individuals were included in the analysis with a median follow-up of 42.9 months and a median of 15 VL tests. In multivariable GEE logistic regression models, gaps in VL testing >9 months were more likely in Quebec (Odds Ratio (OR) = 1.72, p < 0.0001) and Ontario (OR = 1.78, p < 0.0001) than in British Columbia and among injection drug users (OR = 1.68, p < 0.0001) and were less likely among older individuals (OR = 0.77 per 10 years, p < 0.0001), among men having sex with men (OR = 0.62, p < 0.0001), within the first year of cART (OR = 0.15, p < 0.0001), among individuals on cART at the time of the blood draw (OR = 0.34, p < 0.0001) and among individuals with VL < 50 copies/ml at the previous visit (OR = 0.56, p < .0001).ConclusionsSignificant variation in rates of VL testing and the probability of a significant gap in testing were related to geographic region, HIV risk factor, age, year of cART initiation, type of cART regimen, being in the first year of cART, AIDS-defining illness and whether or not the previous VL was below the limit of detection.

[1]  Julio S. G. Montaner,et al.  CD4+ T-Cell Count Monitoring Does Not Accurately Identify HIV-Infected Adults With Virologic Failure Receiving Antiretroviral Therapy , 2008, Journal of acquired immune deficiency syndromes.

[2]  E. Smit,et al.  Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman assay. , 2009, Journal of acquired immune deficiency syndromes.

[3]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.

[4]  B. Gazzard,et al.  Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? , 2008, AIDS.

[5]  J. Montaner,et al.  Health care services utilization stratified by virological and immunological markers of HIV: evidence from a universal health care setting , 2009, HIV medicine.

[6]  Peter Reiss,et al.  Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. , 2008, JAMA.

[7]  J. Raboud,et al.  Nonfinancial Factors Associated With Decreased Plasma Viral Load Testing in Ontario, Canada , 2005, Journal of acquired immune deficiency syndromes.

[8]  W. Hauck,et al.  HIV-1 RNA viral load monitoring in HIV-infected drug users on antiretroviral therapy: relationship with outpatient care patterns. , 2002, Journal of acquired immune deficiency syndromes.

[9]  C. Archibald,et al.  Estimates of HIV prevalence and incidence in Canada, 2005. , 2006, Canada communicable disease report = Releve des maladies transmissibles au Canada.

[10]  J. Montaner,et al.  Increased Reporting of Detectable Plasma HIV-1 RNA Levels at the Critical Threshold of 50 Copies per Milliliter With the Taqman Assay in Comparison to the Amplicor Assay , 2009, Journal of acquired immune deficiency syndromes.

[11]  Curtis Cooper,et al.  Cohort profile: the Canadian Observational Cohort collaboration. , 2011, International journal of epidemiology.

[12]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  N. Ford,et al.  HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. , 2009, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[14]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[15]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[16]  R. Kodet.  Department of Pathology and Molecular Medicine , 2009 .

[17]  C. Archibald,et al.  Estimates of HIV prevalence and incidence in Canada, 2002. , 2003, Canada communicable disease report = Releve des maladies transmissibles au Canada.